CapsoVision Q3 net loss narrows
CV•CapsoVision’s third-quarter revenue rose slightly year over year, while its net loss narrowed. Revenue was $3.57 million and gross profit was $1.76 million.
1. Quarterly results
CapsoVision reported third-quarter revenue of $3.57 million, gross profit of $1.76 million and an operating loss of $7.38 million. Its net loss narrowed from a year earlier.
2. Costs and outlook
Gross margin declined because of higher material costs, a one-time inventory obsolescence charge and higher stock-based compensation. Operating expenses decreased with expense management and completion of the CapsoCam Colon pivotal study. The company expects AI Highlights to accelerate CapsoCam Plus sales growth, with the full impact in 2027, and anticipates clinical expenses will decline after enrollment in the CapsoCam Colon study is complete.
3. CapsoCam Plus use
More than 184,000 patients worldwide had used CapsoCam Plus as of September 30, compared with 151,000 a year earlier.
